Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

A 18F-FDG PET/CT-based radiomics model predicts prognosis of synchronous oligometastatic non-small cell lung cancer.

Sub-category:
Metastatic Non-Small Cell Lung Cancer

Category:
Lung Cancer—Non-Small Cell Metastatic

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e20610

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e20610)

Author(s): Xiaoxia Zhu, Yu Zhang, Zhihao Zheng, Jiaxiu Luo; Radiation Oncology Department, Nanfang Hospital, Southern Medical University, Guangzhou, China; School of Biomedical Engineering, Southern Medical University, Guangzhou, China

Abstract Disclosures

Abstract:

Background: Oligometastatic non-small cell lung cancer (NSCLC) exists high heterogeneity with distinct outcome, and there is a lack of available biomarkers for patient stratification. In this study, we identified a positron emission tomography (PET)/computed tomography(CT)-based radiomics signature capable of predicting overall survival (OS) in patients with synchronous oligometastatic NSCLC. Methods: This study consisted of 46 patients with synchronous oligometastatic NSCLC (≤5 metastases) between 2012-2018. Clinicopathologic data was acquired from medical records and database. A total of 20648 radiomic features were extracted from pretreatment CT and PET images, which were generated from the same PET/CT scanner. A radiomics signature was built by using the least absolute shrinkage and selection operator (LASSO) regression model. Multivariate Cox regression analysis was performed to establish the predictive model. The performance was evaluated with Harrell' concordance index (C-index). Results: 7 radiomics features were selected to build the radiomics signature. Multivariate analysis indicated that the radiomics signature (P = 0.007) was an independent prognostic factor, with a C-index of 0.810. Smoking status (P = 0.01) was the only independent clinicopathologic risk factor for overall survival prediction. Incorporating the radiomics signature with clinicopathologic risk factors resulted in higher performance with a C-index of 0.899. Conclusions: This study developed a radiomics model for predicting OS in synchronous oligometastatic NSCLC, which may serve as a predictive tool to identify individualized treatment strategy. Further internal and external validation of the model are required. Support: 81572279, 2016J004, LC2016PY016, 2018CR033.

CharacteristicValue or no. of patients (%) (n = 46)
Median age at diagnosis of primary NSCLC, years (range)58(26-84)
Median follow up, months(range)21(3.5-67.1)
Sex
Male32(70)
Female14(30)
T Status
19(20)
222(48)
36(13)
49(20)
N Status
012(26)
12(4)
215(33)
317(37)
ECOG PS
06(9)
120(43)
218(39)
32(4)
Smoking status
Never18(39)
Active23(50)
Quit3(7)
Unknown2(4)
Metastatic site
Bone25(54)
Adrenal13(28)
Brain8(17)
Liver2(4)
Others10(22)
Tumor histology
Adenocarcinoma36(78)
Squamous cell carcinoma7(15)
Others3(7)
Driver gene mutations
EGFR15(33)
ALK2(4)
Negative21(46)
Unknown8(17)

Note: Other histologic types included lung clear cell carcinoma, large cell carcinoma and adenosquamous carcinoma.

 
Other Abstracts in this Sub-Category:

 

1. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 102 First Author: Ferdinandos Skoulidis
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

2. Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 110 First Author: Sean Khozin
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

3. RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9000 First Author: Kazuhiko Nakagawa
Category: Lung Cancer—Non-Small Cell Metastatic - Metastatic Non-Small Cell Lung Cancer

 

More...